Dr. Disselhoff is a consultant to Pharmaceutical Industry, specializing in Strategic Regulatory Affairs, Quality Management, Organizational Development and Change Management. She has almost 30 years of experience in Pharmaceutical Industry in Regulatory Affairs, Quality Management and Clinical Research.

Truus Janse-de Hoog, Pharm D, retired recently after having served the Dutch Medicines Evaluation Board (MEB) for nearly 25 years. Truus has extensive international experience serving two terms as chair of Coordination group for human medicines (CMDh) (2005-2008; 2008-2011). From 2006 to 2013 she served as co-chair of the joint HMA/EMA Taskforce on Transparency.

Stefan is currently VP, Global RA-Regional Regulatory Leader-EMEA at Eli Lilly dividing his office time between Lilly’s Bracknell, UK and Bad Homburg, Germany. Stefan has leadership responsibilities for all of Lilly’s regulatory activities in EU, UK, CH, Middle East and Africa for both marketed & development products. He represents Lilly’s regulatory function on various internal governance committees including for global product labelling and international product development strategies. Stefan also represents the company at the EFPIA Innovation Board Sponsored Committee. After studying pharmacy at Johannes Gutenberg University, Mainz, D, he completed his PhD with honors from Ruprecht-Karls-University Heidelberg, Heidelberg, D.